Of particular interest will be outcomes of the SURPASS-2 trial where tirzepatide is studied versus the GLP-1RA semaglutide (ClinicalTrials.gov identifier NCT03987919). Much remains to be learned regarding the molecular mechanism of action that underpins the efficacy of dual GIP/GLP-1 receptor ...